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 Abstract 
Objective: Evidence exists that placebo effects may influence hormone secretion. However, only 
few studies examined placebo effects in the endocrine system, including oxytocin placebo 
effects. We studied whether it is possible to trigger oxytocin placebo effects using a classical 
conditioning paradigm. Methods: Ninety-nine females were assigned to a conditioned, control or 
drug-control group. In the two-phase conditioning paradigm, participants in the conditioned and 
drug-control groups received an oxytocin nasal spray combined with a distinctive smell 
(conditioned stimulus, CS) during three acquisition days, while the control group received 
placebo spray. Subsequently, the conditioned and control groups received placebo spray with the 
CS and the drug-control group- oxytocin spray during three evocation days. Salivary oxytocin 
was measured several times during each day. Pain sensitivity and facial evaluation tests 
previously used in oxytocin research were also administered. Results: On evocation day 1, in the 
conditioned group oxytocin significantly increased from baseline to 5 minutes after CS 
(B[slope]=19.55, S.E.=5.88, p<.001) and remained increased from 5 to 20 (B=-10.42, S.E.=5.81, 
p=.071) and 50 minutes (B=-0.70, S.E.=3.37, p=.84).  On evocation day 2, a trend for increase in 
oxytocin was found at 5 minutes (B=15.22, S.E.= 8.14, p=0.062). No placebo effect was found 
on evocation day 3 (B=3.57, S.E.=3.26, p=0.28). Neither exogenous nor conditioned oxytocin 
affected pain or facial tasks. Conclusions: Results indicate that oxytocin release can be 
conditioned and that this response extinguishes over time. Triggering hormonal release by 
placebo manipulation offers various clinical possibilities, such as enhancing effects of 
pharmacological treatments or reducing dosages of medications.  
Trial Registration: The study was registered as a clinical trial on www.trialregister.nl (number 
NTR5596). 
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 Keywords: classical conditioning; pharmacological conditioning; oxytocin; endocrine system; 
placebo effect 
 
Abbreviations: US = unconditioned stimulus; UR = unconditioned response; CS = conditioned 
stimulus; CR = conditioned response  
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 Introduction 
Extensive research has demonstrated that placebo effects can significantly alleviate subjective 
symptoms of pain (1), fatigue (2), depression (3). There are also studies that indicated that 
placebo affects not only subjective symptoms, but physiological and neurological processes 
underlying these symptoms. For example, placebo analgesia has been demonstrated to be 
triggered by the endogenous opioid (4) and cannabinoid systems (5). Animal research repeatedly 
showed that hormones, for example insulin and corticosterone can be also affected by placebo 
effect (6). Classical or Pavlovian conditioning is proposed to underlie these placebo endocrine 
responses. Conditioning is a learning process in which an association is established between an 
initially neutral stimulus and a physiologically relevant unconditioned stimulus (US) so that after 
repeated pairings, the neutral stimulus becomes a conditioned stimulus (CS) and triggers a 
physiological response similar (or opposite, in case of paradoxical conditioning) to the US; the 
conditioned response (CR).  
Human research on conditioning of placebo endocrine responses is more limited. It was shown 
that it is possible to elicit placebo insulin release by pairing a distinct smell (CS) with intranasal 
insulin spray (US) (7). There is also some evidence showing that cortisol increase (8) and 
decrease (9) can be conditioned, even though a recent study (10) did not find a conditioned 
cortisol response. Other hormonal systems have not been sufficiently investigated in humans and 
it is not known if these findings can be generalized to other endocrine parameters and, moreover, 
the duration of conditioning placebo effects have not been examined in human studies so far. 
Being able to alter hormonal responses by a rather simple behavioral manipulation (e.g., by an 
exposure to a particular smell or taste), has however widespread clinical implications. For 
instance, classical conditioning mechanisms lie at the basis of placebo-controlled dose reduction 
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 schedules, in which a part of the active medication is replaced by placebos while maintaining the 
efficacy of the treatment (11). It is thus important to also explore which hormonal responses can 
be altered by applying the principles of classical conditioning. 
The aim of the current study was to investigated whether it is possible to elicit conditioned 
placebo oxytocin release in humans. Oxytocin is a hormone and neuropeptide produced 
primarily in the hypothalamus and it was initially investigated in the context of the labor 
regulation (12) and mother-infant bonding (13). Oxytocin has especially attracted a lot of 
attention for its prosocial effects. However, despite that it has been proposed to play an important 
role in emotion recognition (14), emotional contact (15) and stress responsiveness (16), these 
results have been heavily criticized for low statistical power and possible biases (17).  No 
consensus has been reached as of yet on the role of oxytocin in human emotional or human 
social behavior. Nevertheless, disruption of oxytocin responses has been found in  several mental 
disorders such as autism (18), schizophrenia (19), borderline disorder (20) and post-traumatic 
stress disorder (21) and currently oxytocin is investigated as a treatment for these conditions (22-
24). In case this potential is proven to be beneficial for patients, being able to influence oxytocin 
release with placebo manipulation would open additional perspectives for the treatment of 
conditions related to emotional deficits. But it is important to note again, the exact relationship 
between oxytocin and prosocial behavior is unclear at this moment and needs careful and critical 
consideration. 
So far only one study demonstrated that oxytocin levels can be manipulated by classical 
conditioning in rats (25). In this randomized controlled trial, we investigated whether is it 
possible to trigger placebo oxytocin release by employing a classical conditioning paradigm. We 
hypothesized that after the repeated coupling of oxytocin nasal spray with a distinctive smell, the 
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 smell alone would trigger endogenous oxytocin release. Moreover, we expected to find the 
strongest conditioned oxytocin release during the first evocation day, and possible extinction 
pattern during the next non-reinforced evocation trials. 
Methods 
Participants  
99 healthy females participated in the study. Only females who were taking oral contraceptives 
were included as they have stable levels of oxytocin during the cycle (26). All females were 
tested while in their pill weeks and not in their stop weeks. Exclusion criteria were: psychiatric 
(DSM-V) conditions, somatic conditions that might interfere with the participant's safety and/or 
the study protocol, Raynaud’s phenomenon, severe neurological or neurosurgical conditions, 
pregnancy or breast feeding, and heavy use of alcohol or drugs. Participants were asked to 
refrain from taking analgesic and anti-inflammatory medication and recreational drugs during the 
two weeks of testing, drinking alcohol and doing physical exercise 24 hour before each session, 
and drinking caffeinated drinks and eating a meal two hours before each session. During the 
screening, participants were asked to sign an informed consent form and at the end of each 
session they received a part of their monetary reward (adding up to 200 euros in total for study 
completion).  
Sample size was calculated on the basis of a pilot study performed in our lab aimed at 
conditioning of cortisol with a similar study design (27). The effect size of the pilot was d = 
0.527 and the sample size was estimated to be 33 participants per group. 
Study design 
The study was a randomized controlled trial. Participants were randomly assigned to one of three 
groups: 1) conditioned group, 2) control group, and 3) drug-control group. The study had a 
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 single-blind design. Participants did not know whether they would receive oxytocin or placebo. 
Researchers knew when participants were included in the drug-control group (due to the absence 
of the CS in the evocation phase) but were blinded regarding the conditioned and control group. 
In line with previous conditioning studies (7, 10), a randomized placebo-controlled conditioning 
paradigm consisting of 2 phases (acquisition and evocation phases) was applied (Figure 1). Both 
acquisition and evocation phases lasted for three consecutive days with a four-day break between 
the last acquisition and the first evocation day to avoid potential drug residual effects from the 
last acquisition day interfering with the first evocation day. For the experimental group, the 
procedure was the following: In the acquisition phase, an association between a US (24IU of 
oxytocin nasal spray) and a CS (smell of rosewood oil) was established. Participants were asked 
to smell the odor with a custom-made olfactometer (28) for a minute before and a minute 
immediately after the oxytocin spray administration. In the evocation phase, participants were 
administered a placebo spray paired with the same smell as in the acquisition phase. A similar 
procedure was used for participants in the control group, but instead of oxytocin spray they 
received a placebo spray during both phases. Participants in the drug-control group were 
administered the oxytocin spray during both the acquisition and evocation phases, but did not 
receive a CS and were tested in a different lab during the evocation phase in order to eliminate 
possible conditioning effects triggered by the CS and the environment of the CS administration. 
This was done in order to avoid a conditioned response in the drug-control group.  
The study was approved by Medical Ethical Committee of Leiden University Medical Centre 
(NL52683.058.15). The randomization was performed by the department of Clinical Pharmacy 
of the Leiden University Medical Center. The block randomization was used with a size of a 
block of 9 participants per block.  
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 Procedure 
Screening. Upon arrival at the lab, participants were asked several questions about their somatic 
and mental health to check the inclusion criteria. Next, participants were asked to fill in several 
questionnaires including questionnaires on demographics and psychological characteristics. A 
saliva sample was taken to establish baseline oxytocin levels. Afterwards, two pain tasks were 
performed to measure the baseline pain sensitivity levels: a Cold Pressor Task (CPT) and a task 
with heat pain stimulation. The aim of the heat pain stimulation was to determine the heat pain 
thresholds that were used in a MRI part of this experiment, which will be reported on separately. 
After this, participants were informed about their eligibility to participate in the study. 
Acquisition phase. The acquisition phase consisted of three consecutive days that lasted 15 
minutes each and started at fixed times between 2 p.m. and 6 p.m. Upon arrival to the lab, a 
baseline saliva sample was taken and the participants were asked questions about their health and 
food and alcohol consumption. Afterwards, participants were exposed to a CS (distinctive smell) 
for a minute. Immediately after the CS, they were administered 24 IU of oxytocin or placebo, 
depending on the group allocation, and were presented with the CS for another minute. The 
interval between the smell administration was no longer than 1.5 minutes.  
Evocation phase. All evocation sessions started at the same time as acquisition sessions between 
2 p.m. and 6 p.m. Identical to the acquisition days, upon arrival at the lab, a baseline saliva 
sample was taken. Then depending on group allocation, participants were administered the CS 
and a placebo spray (in the conditioned and control groups) or oxytocin without the CS in a 
different setting (in the drug-control group to avoid triggering the conditioned response and 
measure the response to the drug only). Three saliva measurements were completed on evocation 
days 1 and 2: at 5, 20 and 50 minutes after the nasal spray administration. In addition, 30 minutes 
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 after the spray administration, participants performed a computer task in which facial 
trustworthiness and attractiveness was evaluated, and 40 minutes after the nasal spray 
administration, they were exposed to CPT. Evocation day 3 started similar to the previous 
evocation days but after the second saliva measurement (5 minutes after the spray 
administration), participants were brought to the MRI facilities of Leiden University Medical 
Centre. Details of the (f)MRI part of this experiment will be reported separately. After the end of 
the last evocation day, participants were fully debriefed. 
The experiment took place in the laboratory facilities of the Social Science department of Leiden 
University. The data collection took place between February, 2016 and August, 2017. 
Intervention 
Unconditioned stimulus. The unconditioned stimulus was a 24 IU of oxytocin (Syntocinon 
Spray) or a placebo nasal spray. The placebo spray looked and tasted identically to oxytocin and 
was prepared by the department of Clinical Pharmacy of the Leiden University Medical Center. 
The nasal spray was administered by the experimenter with two puffs (one puff per nostril) using 
a MAD Nasal mucosal atomization device (Teleflex, Inc., Research Triangle Park). 
Conditioned stimulus. The conditioned stimulus was the administration of a smell of rosewood 
oil for one minute immediately before and one minute directly after the spray administration. 
The smell was administered via a custom-made olfactometer, a device that delivered medicinal 
air with the airflow of 4 litres per minute through a jar with 5 drops of the Rosewood oil 
(Etherische olie Rozenhoud, www.aromaolie.nl) into nasal goggles that participants wore. 
During the smell administration, participants sat under a cylinder connected to the air-
conditioning system of the building, in order to prevent the smell from spreading into the room.  
 
AC
CE
PT
ED
 Materials and measurements 
Saliva samples. Participants were asked to collect between 1.5 and 2 ml of saliva in a cryotube 
using a passive-drool method. Samples were immediately frozen first on dry ice and then in a -
80°C freezer. Salivary oxytocin was assayed using commercial ELISA kits with extraction (Enzo 
Life Sciences, Farmingdale, NY) purchased in November 2017 and April 2018. The addition of 
the extraction procedure, which reduces matrix interference and concentrates the sample, has 
been described previously (2). This method is consistent with currently recommended best 
practices (30). Lower level of detection for oxytocin was 0.5 pg/ml after extraction; extraction 
efficiency was 99%; intra- and inter-assay coefficients of variation were 10.2% and 11.8%, 
respectively. 
The Cold Pressor Task was used to assess pain sensitivity. The waterbath consisted of a 2.7 
liter styrofoam tank with cold water, which was maintained at a fixed temperature of 4°C. 
Participants were asked to hold their dominant hand in the water for 1 minute while every 15 
seconds their pain levels were assessed on a numerical rating scale with a question “How much 
pain do you have now?”. The participant verbally gave an answer on a 0-10 scale with decimals 
(0 = no pain at all, 10 = worst pain ever experienced). The pain intensity scores in response to the 
baseline and post-intervention CPT were calculated as the mean scores of the four pain rating 
measurement points during each CPT.  
A heat pain task was used to determine individual temperatures that would cause a painful but 
bearable sensation (equal of 6 points on the 11-point numeric scale with 0 = no pain at all, 10 = 
worst pain ever experienced). Pain stimuli were administered using a standardized heat pain 
application device (ATS thermode, Medoc Advanced Medical Systems, Ramat Yishai, Israel). 
The thermode was attached to the dorsal site of the left arm of the participants. Participants 
AC
EP
ED
 received a sequence of ascending temperatures with a peak temperature lasting for 5 seconds and 
an inter-stimulus interval of 15 seconds and were asked to evaluate how painful each stimulus 
was. Stimuli that were given a pain score of 6 were used during the fMRI part of the experiment 
that will be reported separately.  
The facial attractiveness and trustworthiness task was used to measure how trustworthy and 
attractive participants find faces of strangers. Participants were asked to rate neutral male and 
female faces on their attractiveness and on trustworthiness using a 7-point Likert scale (1 = not 
attractive/trustworthy; 7 = extremely attractive/trustworthy). In total 32 pictures from the 
Radboud Faces Database (31) were presented in a fixed order and different faces were used on 
evocation days 1 and 2.  
Extraversion and neuroticism were measured with the short version of the Eysenck Personality 
Questionnaire (32). The total score for neuroticism and extraversion ranges from 0 to 12, with 
higher scores indicating higher neuroticism and higher extraversion, respectively.  
Optimism was measured with the revised Life Orientation Test (33). The total score ranges from 
0 to 24, with higher score indicating higher optimism. 
Depression and trait anxiety were measured with the Hospital anxiety and depression scale 
(HADS) (34). The HADS is divided into 2 subscales: the depression subscale and the anxiety 
subscale, both containing 8 items. The score per scale ranges from 0 to 8, with higher scores 
indicating higher depression and anxiety.  
Statistical Analysis 
To compare the groups on baseline characteristics such as baseline oxytocin levels, age, BMI, 
baseline pain sensitivity in response to the CPT, and psychological characteristics an analysis of 
variance (ANOVA) was performed.  
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 To examine the differences in oxytocin levels between the groups during the evocation days, we 
used a linear-mixed effects model approach to account for the dependencies between repeated 
measurements of the same participant. We used the lmer function of the lme4 package (35) in R 
(R Core Team, 2013) for the mixed-models analysis. The multilevel structure of the data was 
defined by measurements (level 1) nested in participants (level 2). Parameters were estimated 
using the full maximum likelihood procedure. Measurement moments were dummy-coded such 
that the slope of each dummy represents the change from one measurement moment to the next, 
and these dummies were added to the regression as separate predictors. Besides a random 
intercept, the models included a random effect for the slope of each dummy variable. Separate 
models were tested per evocation day, first for the two main groups (conditioned and placebo) 
and then the drug-control group was added to examine the changes within this group. We first 
examined the slopes of the oxytocin change between the measurement moments in the three 
groups separately.  
To confirm the results of the multilevel within-group analysis and look at the between-group 
differences, we performed sensitivity analyses with repeated measures analysis of covariance 
(ANCOVA) in which we compared the oxytocin salivary levels after the spray administration 
between the conditioned oxytocin and the placebo groups with the baseline levels as a covariate. 
We ran these analyses separately for evocation days 4, 5 and 6. 
In line with the other conditioning studies (36), we determined conditioning responders and non-
responders on basis of the conditioned oxytocin release after the CS administration. If the 
increase of oxytocin levels from baseline to 5 minutes after the CS administration of a participant 
from the conditioned group exceeded 1 SD of the change in the control group, the participant 
was marked at a responder (37). This was separately done for evocation sessions 1, 2 and 3. 
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 Responders and non-responders from the conditioned group were compared on the basis of their 
baseline characteristics (oxytocin levels, age, BMI, baseline sensitivity in response to the CPT, 
extraversion, neuroticism, optimism, pessimism, depression, and anxiety) with t-tests. 
Additionally, we used Pearson’s correlations to see whether there was an association between 
these variables and the endogenous oxytocin change in the conditioned group on evocation 
session 4. 
To investigate the effects of the manipulations on the pain sensitivity in response to the CPT, a 
repeated measures analysis of covariance (ANCOVA) was performed with the evocation day 
number as a within-subject factor, group as a between-subject factor, and baseline pain 
sensitivity as a covariate. To explore the effect of conditioning on the perceived facial 
attractiveness and trustworthiness, a repeated measures ANOVA with the evocation day number 
as a within-subject factor and group as a between-subject factor was performed. 
 
Results 
Baseline characteristics  
One participant did not complete the baseline cold pressor task due to technical problems; the 
rest of the baseline measurements were completed by all participants. There were no significant 
differences between the three groups in age (F(2, 96)=0.76, p=.47), Body Mass Index (F(2, 
96)=0.85, p=.43), baseline pain sensitivity in response to the cold pressor task (F(2, 95)=0.30, 
p=.74), and questionnaires measuring constructs such as extraversion(F(2, 96)=0.14, p=.87), 
neuroticism (F(2, 96)= 0.85, p=.43), optimism (F(2, 96)=0.03, p=.97), depression (F(2, 96)=0.70, 
p=.50), and trait anxiety (F(2, 96)=0.64, p=.53) (Table 1). 
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 Endogenous oxytocin release  
Due to sample clogging or contamination, 52 samples from 10 participants could not be 
analyzed; all other samples (1235) were included in the analyses. We first tested salivary 
oxytocin levels at baseline during the three acquisition days. The baseline levels of oxytocin did 
not differ between the groups on the first (F(2,92)=2.16, p=.12), second (F(2,93)=0.32, p=.73) or 
third (F(2,93)=0.04, p=.96) acquisition day, indicating that there were no differences in 
endogenous oxytocin levels at baseline and no pharmacological carry-over effects of the 
oxytocin spray administration from one day to the next day during this phase (Table 2).  
The mean oxytocin levels for each evocation day are presented in Figure 3 and Table 2. To 
examine a conditioned oxytocin release in response to the CS in the conditioned group during the 
evocation days, we applied a mixed-models approach. We examined the slopes of the oxytocin 
change between the measurement moments in the three groups, separately. On evocation day 1 in 
the conditioned group, a significant increase in oxytocin levels from the baseline to 5 minutes 
after the CS administration was found (B=19.55, S.E.=5.88, t(187)=3.33 , p<.001), followed by a 
trend to decrease from 5 to 20 minutes (B=-10.42, S.E.=5.81, t(187)=-1.79, p=.071) and non-
significant changes 20 minutes to 50 minutes (B=-0.70, S.E.=3.37, t(187)=-0.21, p=.84) after the 
placebo spray with CS administration. In the control group, the changes from the baseline to 5 
minutes after the placebo spray with CS administration (B=-1.82, S.E.=5.79, t(187)=-0.31, 
p=.75), 5 minutes to 20 minutes (B=-1.21, S.E.=5.75, t(187)=-0.21, p=.83) and 20 minutes to 50 
minutes (B=-3.45, S.E.=3.36, t(187)=-1.03, p=.31) were all not significant. This pattern indicated 
that there was a significant increase of endogenous oxytocin levels that remained for 50 minutes 
in the conditioned group while no such increase was found in the control group. The oxytocin 
levels in the drug-control group greatly increased from baseline to 5 minutes after oxytocin 
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 administration (B=1686, S.E.=236.80, t(272)=7.12, p<.001) and then significantly decreased 
from 5 to 20 minutes (B=-736.15, S.E.=161,47, t(272)=-4.6, p<.001), and from 20 to 50 minutes 
(B=-212.41, S.E.=66.78, t(272)=-3.18, p<.001) after the spray administration.  
On evocation day 2, a trend towards a significant increase of oxytocin levels from baseline to 5 
minutes after the CS administration was found (B=15.22, S.E.=8.14, t(187)=1.87, p=0.062) 
followed by no change of oxytocin levels from 5 minutes to 20 minutes (B=-12.05, S.E.=7.80, 
t(187)=-1.54, p=0.12) and a significant drop of oxytocin levels from 20 to 50 minutes (B=-5.98, 
S.E.=1.87, t(187)=-3.21, p<0.001) in the conditioned group. In the control group, the changes 
from the baseline to 5 minutes (B=0.47, S.E.=8.11, t(187)=0.06, p=0.95), 5 minutes to 20 
minutes (B=-0.61, S.E.=7.78, t(187)=-0.08, p=0.94), and 20 minutes to 50 minutes (B=-1.76, 
S.E.= 1.84, t(187)=1.84, p=0.34) were all not significant. This pattern indicated a trend for 
increased conditioned oxytocin levels in the conditioned group that remained present from 5 
minutes until 20 minutes after the CS administration. In the drug-control group, the oxytocin 
levels increased significantly from baseline to 5 minutes after the spray administration 
(B=1480.26, S.E.=225.20, t(272)=6.57, p<0.001) followed by a significant decrease from 5 to 20 
minutes (B=-536.16, S.E.=142.43, t(272)=-3.76, p<0.001), and from 20 to 50 minutes (B=-
242.38, S.E.=72.11, t(272)=-3.36, p<0.001).  
Finally, on the evocation day 3, that included two measurement moments (baseline and 5 
minutes), no significant changes from baseline to 5 minutes after the CS administration were 
found, neither in the conditioned (B=3.57, S.E.=3.26, t(59)=1.10, p=0.28) nor in the control 
group (B=3.02, S.E.=3.14, t(59)=0.96, p=0.34). In the drug-control group, there was a significant 
increase in oxytocin levels from the baseline to 5 minutes after the spray administration 
(B=1552.25, S.E.=261.37, t(87)=5.94, p<0.001).  
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 The sensitivity analyses using a repeated measures ANCOVA comparing the conditioned and 
control groups on the evocation day 1 showed that the salivary oxytocin levels in the conditioned 
group were higher comparison to the control group (F(1, 61)=7.84, p=.007, ηp2 =0.114) after 
controlling for the baseline levels. No effect of time (F(2, 61)=0.642, p=0.53, ηp2 =0.01) or a 
time x group interaction (F(2, 61)=1.10, p=0.56, ηp2=0.01) on oxytocin levels during evocation 
session 1 were found. Salivary levels of the conditioned and control group did not significantly 
differ on evocation day 2 (F(1, 61) =1.76, p=.19, ηp2 =0.028). No significant effect of time (F(2, 
61)=0.86, p=.43, ηp2 = 0.014;) or a time x group interaction (F(1, 61)=1.53, p=.22, ηp2 =0.024) 
on the salivary levels on evocation day 2 were found. Finally, the two groups did not differ in the 
salivary oxytocin levels on evocation day 3 F(1, 61)=1.27, p=.27, ηp2 =0.021) after controlling 
for the baseline levels. 
Participants in the conditioned group could be divided into responders and non-responders. Ten 
responders were found on the evocation day 1, five responders on the evocation day 2 (the same 
as on evocation day 1) and one responder on evocation day 3. No significant differences were 
found between responders and non-responders on baseline characteristics and questionnaires: 
age, Body Mass Index, baseline oxytocin levels, baseline pain sensitivity in response to the CPT, 
extraversion, neuroticism, optimism, pessimism, depression, and trait anxiety (all ps>.10).  
Additionally, no significant correlations between the change in the endogenous oxytocin levels 
in the conditioned group on evocation session 4 and these baseline variables were found (all ps > 
.1) 
Pain perception  
Repeated measures ANCOVA demonstrated that there was no effect of the group (F(2,94)=0.13, 
p=.88), the day (F(1, 94)=0.51, p=.48) and the group-by-day interaction (F(2,94)=0.53, p=.70) on 
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 the pain sensitivity ratings, indicating that neither endogenous conditioned oxytocin release, nor 
exogenous oxytocin administration influenced pain sensitivity (Table 3). 
Perceived facial trustworthiness and attractiveness  
Data of 94 participants were available for this analysis. Repeated measures ANOVA 
demonstrated that participants in all groups rated faces as less trustworthy on the second 
evocation day in comparison to the first evocation day (F(1,92)=57.27, p<.001). However, the 
three groups did not differ in their trustworthiness ratings (F(2,92)=0.01, p=.99) nor was the 
group-by-day interaction significant (F(2,93)=2.99, p=.062). There was no effect of the group 
(F(2,92)=0.38, p=.38), the day (F(1,92)=3, p=.092) or group-by-day interaction (F(2,92)=0.22, 
p=.80) on the perceived facial attractiveness ratings (Table 3).  
 
Discussion 
The present study demonstrated for the first time that placebo effects can trigger endogenous 
oxytocin release. After three days of receiving oxytocin nasal spray with a distinctive rosewood 
oil smell, participants exhibited a conditioned increase of salivary oxytocin levels in response to 
the smell combined with a placebo. Moreover, this study demonstrated that this conditioned 
oxytocin response followed an extinction pattern during the not-reinforced trials of the evocation 
phase.  
The present experiment supports the existing evidence that hormonal responses can be 
modulated by classical conditioning in humans. Previous studies showed that insulin (7), cortisol 
(8, 9), and growth hormone levels (9) can be altered by conditioning in humans. However, no 
such evidence existed for oxytocin in humans. We found the strongest placebo effect on the first 
evocation day as hypothesized. A trend towards an increase of oxytocin release over baseline 
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 was found on the second evocation day. No increase was found anymore on the third evocation 
day. These results are the first to demonstrate that endogenous placebo oxytocin release 
decreases when not reinforced upon subsequent trials. These findings correspond with the theory 
of extinction of conditioned responses (37). No previous data on extinction of hormonal placebo 
effects in humans are available, since human studies on conditioning of hormonal responses 
investigated conditioned responses for only one evocation day. Future research should replicate 
these findings and investigate whether conditioned responses of other hormones follow the same 
extinction pattern.  
Literature proposes that intranasal administration of oxytocin triggers endogenous oxytocin 
release by feed-forward mechanisms, so that circulating oxytocin stimulates further oxytocin 
release (38-40). In our study, intranasal oxytocin was used as the US and endogenous oxytocin 
release was expected to be a conditioned response. The results supported this hypothesis: we 
found a conditioned increase of endogenous oxytocin levels in response to a CS. 
The salivary oxytocin levels found in the drug-control group are consistent with the results found 
in previous research (39, 40): the oxytocin levels increased 100 times (10000%) from baseline 
after the oxytocin administration. The conditioned response was much smaller: salivary oxytocin 
levels increased two times (200%) compared to baseline at the highest peak. Noticeably, the 
conditioned response was nevertheless still higher than the magnitude of the endogenous 
oxytocin release in response to behavioral manipulation measured in blood: a 47% increase of 
endogenous oxytocin was found in response to watching an emotional video (41) and a 17% 
increase was found in response to massage (42). These results show that classical conditioning 
can be an effective way to induce oxytocin release on demand, however, future research should 
investigate whether these conditioned responses are large enough to cause any clinically 
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 significant effects and whether effects of similar magnitude can be induced with fewer 
acquisition trials. Moreover, the large standard errors in the conditioned group indicate the 
presence of responders and non-responders to the conditioning manipulation amongst the 
participants. These results add to the accumulative evidence on responders and non-responders to 
pharmacological conditioning (10, 36). Several factors may influence the response to 
conditioning. For example, baseline interleukin-2, noradrenaline and anxiety have been shown to 
predict the conditioned interleukin-2 response (36). Furthermore, baseline cortisol levels have 
been linked to the responsiveness to cortisol conditioning (10). In the present study, we were 
unable to find possible predictors of the conditioning response. More knowledge regarding what 
factors predict a conditioned response is needed. 
Finally, we found no effect of conditioned endogenous oxytocin release and exogenous oxytocin 
on pain sensitivity and perceived facial attractiveness and trustworthiness. These two tasks were 
included into the experiment as additional measures of the behavioral and physiological effects 
of oxytocin conditioning. Previous studies reported that these parameters were influenced by 
exogenous oxytocin administration (43, 44). Therefore, we expected that conditioned oxytocin 
responses could increase perceived facial trustworthiness and attractiveness and decrease pain 
sensitivity, mimicking th effects of exogenous oxytocin administration. We were unable to 
demonstrate that exogenous oxytocin administration or conditioned oxytocin release affect 
perceived facial attractiveness and trustworthiness or pain sensitivity in the current dose and 
method of administration. Previous study on the perceived facial attractiveness and 
trustworthiness included larger groups (44) and as the power calculation of this study was not 
aimed to these secondary outcome parameters, the sample might have been too small to 
demonstrate these effects. Even though trust-enhancing effects of oxytocin have been 
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 demonstrated in a meta-analysis (45), Lane and colleagues (46) report several failures to 
replicate these results. Therefore, our results contribute to the mixed evidence regarding the 
trust-enhancing effects of oxytocin. Moreover, our findings regarding oxytocin effects on pain 
sensitivity are partly in line with recent findings that also show no effects of exogenous oxytocin 
on pain sensitivity (47, 48).  
Several limitations of the current study have to be addressed. First of all, the results cannot be 
generated to men and women who do not take hormonal contraceptives. As this was a first proof-
of-concept study, we limited our sample to female participants who take hormonal contraception 
as they have been shown to have stable levels of oxytocin during the cycle (28). Future research 
should expand our findings and examine whether endogenous oxytocin levels are conditionable 
in men and women who are not using contraception. Secondly, the conditioned responses we 
found were very short-lasting and seemed to start extinguishing already after the first evocation 
day. In order to apply classical conditioning mechanisms to clinical practice, it is important to 
find possible ways to prolong these effects, such as including more acquisition trials, partial 
reinforcement (46) or subtherapeutic conditioning (49). Another limitation concerns the reported 
levels of oxytocin measured in the drug control group. The found increase of oxytocin in the 
drug control group may potentially be partly explained by the contamination of the saliva by the 
intanasally administered oxytocin. Realizing this limitation, we did not directly compare the 
experimental group with the drug control group. One more limitation is that we did not measure 
the expectations of the participants regarding the treatment they received. Expectations are one 
of the important underlying mechanisms of placebo effect (3, 11). Only one study so far 
measured the effect of expectations on conditioned hormonal responses and found no effect (9). 
Possibly, as the hormonal changes happen without conscious awareness, the role of expectations 
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 in endocrine conditioning is less important than in placebo effects of such subjective symptoms 
as pain. However, we cannot exclude the possibility that expectations of participants had an 
influence on our results. Finally, there is an important limitation of the findings on the behavioral 
effects of intranasal oxytocin in general. There is a debate in the literature about the replicability 
and reliability of the studies that showed behavioral effects of intranasal oxytocin. Several 
reviews (17, 46, 50) report failures to replicate the results of the studies on behavioral effects of 
oxytocin, and discuss the potential role of low statistical power of the published studies and 
possible publication bias. Additionally, an often-cited study on the trust enhancing effects of 
oxytocin (51), have been criticized for not-standard interpretation of the statistics (52). Leng (54) 
discuses that according to animal studies that measured oxytocin levels in cerebrospinal fluid 
after the exogenous oxytocin administration, only a small fraction of oxytocin reaches 
cerebrospinal fluid and it is unclear how these small amounts might cause behavioral changes. 
Additionally, the timing of behavioral effects (e.g., 55, 56) that are usually found at 45 minutes 
after intranasal oxytocin administration, does not correspond to the increase in cerebrospinal 
fluid oxytocin levels that occurs 75 minutes after the oxytocin administration (57). In this study 
we have also failed to find any behavioral effects of oxytocin and our results add to the 
contradictory evidence on the possible pain-reducing and trust-enhancing effects of oxytocin. 
Regarding the clinical implications of the current study findings, there is some tentative evidence 
that oxytocin might have a potential to improve social cognitions in autism (58), borderline 
personality disorder (23) and schizophrenia (22).  Also, treatment with oxytocin was shown to 
increase insulin sensitivity and decrease weight in obese adults (59), reduce inflammation (60, 
61) and increase healing processes (62) in animals. However, other studies were unable to find 
beneficial behavioral effects of oxytocin (47, 50) which is more in line with our findings. In sum, 
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 the findings on the clinical relevance of oxytocin are not conclusive as no consensus has been 
reached at this moment.  
Placebo-controlled dose reduction is one of the possible ways to use placebo effects directly in 
clinical practice. It is a drug-schedule in which patients first undergo a standard treatment and 
afterwards a part of their regular medication is replaced with placebo, following for example a 
partial reinforcement schedule (63). Due to pharmacological conditioning, the response to 
placebo is hypothesized to mimic the drug response leading to maintenance of the treatment 
effectiveness with a potential reduction of associated side effects. Only a few trials so far 
investigated the efficiency of placebo-controlled dose reduction and first evidence demonstrated 
that it can be as efficient as a standard treatment for attention deficit and hyperactivity disorder, 
psoriasis, and chronic insomnia (64-66). Alternatively, conditioning-triggered placebo effects 
can be used in the enhancement of treatment effects of already existing therapies without the 
increase in the medication dose: it was demonstrated that classically conditioned 
immunosuppression enhances the effects of the routine treatment of renal transplant patients 
(67). Based on our findings indicating the possibility to condition hormonal responses, new 
placebo-controlled dose reduction trials or trials aimed at enhancement of treatment effects could 
be developed especially for symptoms requiring hormonal treatments. 
In sum, the present study is the first proof of principle that salivary oxytocin levels can be 
conditioned by coupling intranasal oxytocin administration with a distinctive smell, and that the 
conditioned oxytocin extinguishes when not reinforced. This finding supports the limited 
evidence in animals and humans that hormonal responses can be influenced by the placebo 
effect. Employing the placebo effect in clinical practice might be an easy and efficient way to 
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 enhance the effects of pharmacological treatments and reduce the dosages of medications, 
reducing costs and side effects of standard treatments. 
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 Figure Legends 
Fig. 1. Study design  
Fig. 2. Timeline of the experimental days.  
Fig. 3. Salivary oxytocin levels (pg/ml) on evocation days 1 (A, B), 2 (C, D) and 3 (E, F) 
separately for each group (n= 99). Error bars indicate standard errors. 
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 Table 1. Baseline characteristics across the groups with standard deviations. 
 
 Conditioned group  
(n = 33) 
M (SD) 
Control group  
(n = 33) 
M (SD) 
Drug-control group 
(n = 33)  
M (SD) 
Age 21.2 (2.8) 21.7 (1.9) 21.9 (2.5) 
Body mass index 22.4 (2.5) 21.8 (2.1) 22.5 (2.4) 
Screening pain sensitivity 4.5 (1.6) 4.5 (2.3) 4.7 (2.2) 
Extraversion 10.2 (2.9) 10.2 (1.9) 9.9 (2.7) 
Neuroticism 3.3 (2) 2.8 (1.7) 2.8 (1.9) 
Optimism 8 (1.5) 8 (1.7) 8 (1.4) 
Depression 1.1 (1.2) 0.8 (1.0) 0.9 (0.8) 
Trait anxiety 2.9 (1.8) 2.5 (2.2) 2.9 (1.8) 
 
  
AC
CE
PT
ED
 Table 2. Mean salivary oxytocin levels (pg/ml) across the groups and measurements with 
standard deviations. 
 
Session Measurement Conditioned 
group (n = 33) 
Control group (n 
= 33) 
Drug-control 
group (n = 33) 
Acquisition 1  Baseline 21.4 (35.7) 12.2 (12.1) 10. 4 (6.6) 
Acquisition 2  Baseline 13.8 (8.0) 16.2 (18.8) 14.2 (9.6) 
Acquisition 3  Baseline 16.1 (14.6) 14.8 (11.0) 15.7 (24.8) 
Evocation 1 Baseline 11.9 (8.4) 16.4 (18.8) 11.7 (6.8) 
 5 minutes 31.5 (46) 14.6 (7.5) 1805.7 (2275.3) 
 20 minutes 21.1(27.6) 13.4 (8.3) 1118.8 (1835.3) 
 50 minutes 20.4 (23.9) 9.9 (5.1) 857.8 (1522.2) 
Evocation 2  Baseline 13.4 (6.7) 12.8 (7.9) 13.6 (8.7) 
 5 minutes 28.6 (64.4) 13.7 (6.5) 1595.7 (2139.6) 
 20 minutes 16.5 (14.3) 12.6 (5.6) 1069.3 (1622.6) 
 50 minutes 10.6 (7.3) 10.9 (5.5) 818.3 (1598.2) 
Evocation 3  Baseline 12.4 (12.2) 16.1 (20.7) 15.1 (12.7) 
 5 minutes 12.4 (7.3) 19.4 (42.6) 1762.9 (2519) 
 
  AC
CE
PT
ED
 Table 3. Mean task scores across the groups and evocation days with standard deviations. 
 
 
 
 
Task Session Conditioned group Control group Drug-control group 
Pain sensitivity Evocation 1 4.8 (1.9) 5.0 (2.2) 4.9 (2.2) 
 Evocation 2 4.7 (1.8) 4.8 (2.3) 4.9 (2.2) 
Attractiveness  Evocation 1 2.8 (0.5) 3.0 (0.6) 3.0 (0.6) 
score Evocation 2 2.8 (0.6) 2.9 (0.6) 3.0 (0.6) 
Trustworthiness  Evocation 1 4.0 (0.7) 4.0 (0.8) 4.1 (0.6) 
score Evocation 2 3.7 (0.8) 3.8 (0.9) 3.6 (0.5) 
AC
CE
PT
ED
